.jpg)
STAT+: Institutional investors urge pharma boards to tie executive compensation to global Covid vaccine equity
More than 65 institutional investors are urging the directors of companies making Covid-19 vaccines to…
Category: STAT+
STAT+: Pharmalittle: More top hospitals aren’t offering Biogen Alzheimer’s drug; Pfizer may lower Covid pill price in poor countries until supplies rise
Hello, everyone, and how are you today? Cloudy skies are hovering this morning over the…
STAT+: Blueprint Medicines seeks ‘continuity, not change’ in CEO transition
For Jeff Albers, the decision to step down as the CEO of Blueprint Medicines after…
STAT+: ‘It’s almost negligible’: More top hospitals aren’t offering controversial Alzheimer’s drug Aduhelm
WASHINGTON — Almost no one is prescribing Aduhelm, the controversial new Alzheimer’s treatment that roiled…
STAT+: Pharmalittle: U.S. doubles order of Pfizer Covid-19 pill; court revives suit claiming drug makers funded terrorism in Iraq
Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle…
STAT+: The health tech tracker for the first quarter: 13 decisive industry events and deals to watch
As we enter the pandemic’s third year, we’ll be watching to see whether skyrocketing digital…
STAT+: 3 CRISPR editing innovations to watch in 2022
During the first year of the Covid-19 pandemic, many of the world’s scientists — including…
STAT+: Chatbots, surveys, and texts: Telehealth companies cut costs by reimagining the front desk
Telehealth companies struggling to stand out in a crowded virtual care market are increasingly leaning…
STAT+: Some drug makers quietly resumed donations to lawmakers who denied Biden’s election victory
Four major drug makers each donated tens of thousands of dollars last year to Republican…
STAT+: Why the conviction of Elizabeth Holmes hinged on defrauding Theranos investors, not patients
The trial of Elizabeth Holmes resulted in a mixed verdict, but one outcome is clear:…
STAT+: Applied Therapeutics tried to muzzle short sellers — but the truth still came out
When short sellers began raising questions about New York-based Applied Therapeutics’ treatment for a rare…
STAT+: Pharmalittle: Pharma raises median drug prices by 4.9%, so far; Covid forces some lawmakers to ponder pharma gifts
Top of the morning to you, and a fine one it is. Clear skies and…
STAT+: FDA’s vaccines and biologics chief talks Covid-19, 2022 priorities, and getting back to gene, cell therapy review
WASHINGTON — No part of the Food and Drug Administration has been challenged by the…
STAT+: Texas is trying to create the next research triangle for biotech. Will it work?
Do you live in a city vying to be the country’s next biotech hub? Get…
STAT+: HHS appeals rulings over drug discount program just as AbbVie is latest to cut discounts
A heated clash over a U.S. government drug discount program has intensified after a federal…
STAT+: Pharmalittle: New Covid-19 vaccine developers expect nothing in return; COVAX distribution falls short of goals
Good morning, everyone, and nice to see you again after a long break. For those…
STAT+: The biotech scorecard for the first quarter: 19 stock-moving events to watch
Happy New Year! Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events,…
Opinion: STAT+: Building a better on-ramp for health innovation
The pandemic crisis has illuminated a stark reality that innovators, particularly those in biotech, have…
STAT+: Three missing pieces the digital therapeutics sector needs to succeed in 2022
Smartphone apps aren’t a default way of managing diabetes — not yet, anyway. Though telehealth…
STAT+: 3 biotech trends to watch in 2022
It’s been a weird year for biotech stocks. One major index peaked in February, but…
STAT+: 3 challenges for hospitals in 2022
WASHINGTON — Hospitals didn’t get the relief the rollout of Covid-19 vaccines seemed to promise at…
STAT+: In a ‘baffling’ disappointment, BridgeBio’s heart drug misses primary goal in pivotal study
A treatment developed by BridgeBio for an increasingly common heart disease missed its primary endpoint…
.jpg)
STAT+: How Brigham Health helped create a Chinese hospital for elites — and almost nobody came
It was worlds away from the Boston medical hub: There were no traffic-clogged intersections, no…
STAT+: 3 contentious decisions the FDA will make in 2022
WASHINGTON — It’s going to be a bumpy 2022 for the Food and Drug Administration….
STAT+: 7 challenges that could make or break Biogen’s 2022
Can Biogen pull itself back from the brink? The company is ending 2021 with dismal…
STAT+: Pharmalittle: Japan panel nixes Biogen Alzheimer’s drug; Oxfam urges SEC to probe Moderna over patent dispute remarks
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: 4 epilepsy-focused biotech companies to watch
More companies than ever before are training their sights on developing treatments for epilepsy, which…
STAT+: Harvard nanoscientist found guilty of lying about financial ties to Chinese university
A federal jury found Harvard University professor and renowned nanoscientist Charles Lieber guilty of all…
STAT+: Verily shakes up its leadership team, with a new president and a shift for CEO Conrad
Alphabet’s life sciences arm Verily is in the midst of a shakeup of its leadership….
STAT+: Oxfam wants the SEC to investigate Moderna for ‘misleading’ investors about its Covid patent dispute with NIH
Oxfam America has filed a complaint with securities regulators accusing Moderna (MRNA) of providing “misleading…
STAT+: By endorsing a first injectable for HIV prevention, FDA creates alternative to pills and a battle among drug makers
In a notable development, the first long-acting injectable shot for preventing HIV was approved by…
STAT+: Pharmalittle: Moderna says booster shot raises antibody levels to thwart Omicron; Sanofi buys yet another biotech
Rise and shine, everyone, another busy day is on the way. Although it may feel…
Opinion: STAT+: Forget the hype and embrace the reality: How AI can improve health outcomes right now
The story of artificial intelligence (AI) driving better health care outcomes has been a convoluted…
STAT+: Worst biopharma CEO of 2021? There are too many to choose just one
I’m not naming the Worst Biopharma CEO for 2021. I chose 10. It’s been that…
STAT+: It’s the cardiovascular version of Alzheimer’s — and, for a biotech with a promising drug, it could be a windfall
Surprise diagnoses have a way of making Ph.D. candidates out of everyday people. Walter Feigenson’s…
STAT+: University of Chicago professor charged with insider trading over a cancer drug trial
A University of Chicago associate professor who worked as a clinical trial investigator for Five…
STAT+: Oracle to buy electronic health records giant Cerner for $28.3 billion
In what will be the year’s largest deal in health tech, software giant Oracle has…
STAT+: Pharmalittle: Biogen cuts price of Alzheimer’s drug in half and plans cost cuts; Moderna test suggests booster works against Omicron
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Biogen slashes price of Alzheimer’s drug Aduhelm in half, plans $500M in cost-cutting
Biogen said Monday that it has reduced the price of its Alzheimer’s drug Aduhelm by…
STAT+: AbbVie asks the U.S. International Trade Commission to investigate Alvotech’s plans for a biosimilar Humira
In its latest bid to defend its franchise product, AbbVie (ABBV) has filed a complaint…
STAT+: Here are the finalists for best biopharma CEO of 2021. And a winner
It’s that time of the year again when we recognize the Best Biopharma CEO of…
STAT+: Pharmalittle: Judge reverses Purdue Pharma bankruptcy plan; FDA eases access restrictions on abortion pills
And so, another working week will soon draw to a close. Not a moment too…
Opinion: STAT+: 8 reasons ‘move fast and break things’ doesn’t work for health care companies
Entrepreneurs at tech startups are likely to hear the Mark Zuckerberg adage that it’s important…
STAT+: Prescription apps to treat disease face uncertainty as they fight for insurance coverage
In August, Pear Therapeutics, the company at the forefront of creating prescription software to treat…
STAT+: Biden administration seeks a legislative path for novel antibiotic drug development
Amid rising concerns over antibiotic resistance, the U.S. Department of Health and Human Services is…
STAT+: FDA rebukes Endo for ‘anticompetitive practices,’ asks FTC to investigate
In an unusual move, the U.S. Food and Drug Administration has openly suggested that a…
STAT+: Pharmalittle: Biogen to start large trial to confirm Alzheimer’s drug benefits; FDA to decide on easier access to abortion pill
Top of the morning, and a fine one, it is. The sun is trying to…
As Aduhelm faces doubts, Biogen plans another pivotal trial for 2022
Biogen said Thursday that it expects to begin a large clinical trial next May to…
STAT+: Medicine’s first autonomous AI could prevent blindness due to diabetes — if it can reach those most in need
Once feared as a job-erasing technology devoid of clinical nuance, autonomous artificial intelligence in medicine…
STAT+: Health tech’s sky-high projections in 2021 have already been punctured
The health technology sector has seen extraordinary enthusiasm among private and public investors this year….